Last $0.11 USD
Change Today +0.005 / 5.00%
Volume 9.1K
BJCT On Other Exchanges
Symbol
Exchange
OTC US
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

bioject medical technologies (BJCT) Snapshot

Open
$0.08
Previous Close
$0.10
Day High
$0.11
Day Low
$0.08
52 Week High
03/19/14 - $0.45
52 Week Low
12/26/13 - $0.07
Market Cap
9.1M
Average Volume 10 Days
32.4K
EPS TTM
$0.01
Shares Outstanding
86.3M
EX-Date
--
P/E TM
10.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOJECT MEDICAL TECHNOLOGIES (BJCT)

Related News

No related news articles were found.

bioject medical technologies (BJCT) Related Businessweek News

No Related Businessweek News Found

bioject medical technologies (BJCT) Details

Bioject Medical Technologies Inc., together with its subsidiaries, engages in developing, manufacturing, and distributing needle-free injection therapy systems primarily in the United States. The company provides Biojector 2000 system, a refinement of jet injection technology that enables healthcare professionals to deliver measured variable doses of medication through the skin either intramuscularly or subcutaneously without a needle; and needle-free drug reconstitution system that allows the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. It also offers Vitajet, which is composed of two components, a portable injector unit and a disposable syringe; and ZetaJet, a compact and spring-powered injection device intended to deliver vaccines and injectable medications either subcutaneously or intramuscularly. In addition, the company is developing Iject needle-free injection system, a single prefilled disposable injector for self-injection; Jupiter Jet, a pistol-shaped, or streamlined ergonomic gas-powered injection device for patient and professional use; and pre-filled Biojector syringes. It has a strategic alliance with MPI Research. The company was founded in 1985 and is based in Tualatin, Oregon.

bioject medical technologies (BJCT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioject medical technologies (BJCT) Key Developments

Bioject Medical Technologies Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Bioject Medical Technologies Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of $458,000 compared to $458,000 a year ago. Operating loss of $123,000 compared to $274,000 a year ago. Net loss allocable to common shareholders was $189,000, compared to $320,000 a year ago. Basic and diluted net loss per share allocable to common shareholders was $0.01 compared to $0.02 a year ago. Operating results were negatively affected by unexpected delays at the company’s contract manufacturing site, resulting in $108,000 less in revenues than forecasted and associated operating expenses of $45,000. For the nine months, the company reported net sales of $1,312,000 compared to $1,146,000 a year ago. Operating loss of $657,000 compared to $1,237,000 a year ago. Net loss allocable to common shareholders was $836,000, compared to $1,349,000 a year ago. Basic and diluted net loss per share allocable to common shareholders was $0.03 compared to $0.07 a year ago.

Bioject Medical Technologies Inc. announced delayed 10-Q filing

On 11/12/2014, Bioject Medical Technologies Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Bioject Medical Technologies Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Bioject Medical Technologies Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the second quarter, the company reported net sales of $513,000 for the quarter ended June 30, 2014, compared to net sales of $238,000 for the quarter ended June 30, 2013. The company reported an operating loss of $275,000 in the second quarter of 2014, compared to an operating loss of $493,000 in the second quarter of 2013. Net loss allocable to common shareholders for the second quarter of 2014 was $331,000, compared to $526,000 in the comparable 2013 period. Basic and diluted net loss per share allocable to common shareholders for the quarter ended June 30, 2014 was $0.01 compared to $0.03 for the same period in 2013. For the six months ended June 30, 2014, the company reported net sales of $855,000, compared to net sales of $688,000 in the comparable period of 2013. Operating loss for the six months ended June 30, 2014 was $534,000, compared to $962,000 in the comparable period of 2013. Net loss allocable to common shareholders was $647,000, or $0.03 per basic and diluted share, compared to $1,028,000, or $0.05 per share for the comparable period of 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BJCT:US $0.11 USD +0.005

BJCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.65 USD +0.03
View Industry Companies
 

Industry Analysis

BJCT

Industry Average

Valuation BJCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOJECT MEDICAL TECHNOLOGIES, please visit www.bioject.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.